Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that treprostinil, a prostacyclin analog, significantly delayed fibroblast migration from healthy donors but did not affect fibroblast migration derived from diabetic foot ulcers.

In this study, nearly one-third of patients with severe alopecia areata treated with ritlecitinib achieved complete scalp hair regrowth at least once over three years, and most maintained regrowth or stayed at low hair loss levels subsequently.

This study found that vismodegib promotes Basal cell carcinoma regression by inducing tumor differentiation but leaves a small population of quiescent cells that can drive relapse, which can be eliminated by adding a Wnt signaling inhibitor.

In this case report, the researchers described the use of tofacitinib in treating a 14-year-old boy from India with severe alopecia areata, achieving complete hair regrowth within 2 months without serious adverse events, highlighting tofacitinib's potential benefits and safety in adolescent cases.

This review highlights the potential of amphiregulin as a therapeutic target, noting its role in both fibrotic and malignant diseases, and discusses promising early findings but reports no new clinical results.

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This article discusses the paradoxical effects of valproic acid on hair, reporting both drug-induced hair loss and the potential for hair growth when used topically, but presents no original research findings.

This study reported that a modified version of Thymosin beta 4, called PEG-rTβ4, demonstrated potential as a treatment for acute myocardial infarction by improving cardiac function and reducing cell death via specific biochemical pathways, suggesting its promise in drug development efforts.

This study found that Janus Kinase inhibitors, tofacitinib and baricitinib, showed effectiveness and safety in treating severe alopecia areata in a real-world setting, with optimal tolerability noted in younger individuals.

This study synthesized and verified the structures of Setipiprant's major and minor metabolites, confirming their regio- and enantioselectivity from earlier proposals in a clinical study.

In this study, peptide-based nanoparticles were successfully used to deliver the CRISPR-Cas9 system into cancer cells, effectively targeting and editing KRAS mutations, suggesting promising therapeutic potential for cancer treatment.

In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.

This study found that baricitinib significantly reduced alopecia severity in JAK inhibitor-naïve patients compared to those previously treated with tofacitinib, indicating that switching JAK inhibitors can be safe and may be beneficial for selected patients with partial prior responses.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

This study observed significant repigmentation in localized stable vitiligo lesions treated with oral baricitinib, with even more improvement when combined with topical tacrolimus, and reported no side effects.

This narrative review highlights the potential of naturally occurring compounds to target specific molecular pathways and overcome resistance in advanced and recurrent papillary thyroid cancer, offering new therapeutic possibilities beyond traditional treatments like surgery and lifelong hormone replacement.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This case report describes a young Indian boy with resistant alopecia areata who experienced nearly complete hair regrowth within 5 months of treatment with oral tofacitinib.

In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.

In this study using a mouse model, RIPK1 inhibitors were found to delay the onset of alopecia areata, reduce immune cell numbers in affected skin, and increase hair length, indicating a potential therapeutic role in preventing alopecia areata.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

This study aims to assess the real-world effectiveness of baricitinib, a JAK inhibitor, for promoting regrowth of nasal, genital, and beard hair in patients with severe alopecia areata, expanding on findings from the BRAVE-AA clinical trial. Results are not reported.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

In this case report, a 65-year-old woman with non-small cell lung cancer experienced scarring alopecia with papulo-pustular lesions on the scalp due to gefitinib treatment, marking it as a rare instance of gefitinib-induced erosive pustular dermatosis of the scalp.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.